December 30, 2011

AlloDerm Explained

Modern Medicine has come a long way. The Pharmaceutical Industry as we know it began in 1928 when Sir Alexander Fleming discovered Penicillin. The discovery of this antibiotic from the mould, Penicillium notatum, was stated by Time Magazine as the discovery that would change the course of history. This infection-fighting antibiotic inspired other scientists to produce their own synthetic versions of this drug that would go on to treat some of the most common and serious infections and diseases known to mankind.

Since 1994, the Biotechnology Company, LifeCell, has been a pioneer in regenerative medicine. Their success can be attributed to rising sales of their flagship product, AlloDerm.
AlloDerm Regenerative Tissue Matrix, is an Accellular Human Dermis, which is an organic tissue graft produced through a unique non-damaging process that allows the body to mount its own tissue regeneration process. Essentially, the skin, which is derived from cadavers, goes through a process to remove all off the epidermis and dermis skin layers leaving only the collagen and elastin framework of the skin. This process removes that elements of the skin that would ordinarily be rejected by the recipient leaving only what will be accepted by the new body, and ultimately assist in the cellular rebuilding process.

In 1994 AlloDerm was originally developed and used for grafts for burn patients. In the early 2000s it began being marketed for internal procedures. Currently, AlloDerm’s most common uses include hernia repair, abdominal wall reconstruction, and postmasectomy breast reconstruction. AlloDerm is also used by dentists for soft tissue and gum reconstruction.
As stated on LifeCell’s website. AlloDerm has been used successfully in more than one million grafts and implants to date. However, nothing is perfect, and it is impossible to measure success without acknowledging failures.

Continue reading "AlloDerm Explained" »

September 30, 2011

Topamax and Birth Defects to be Discussed at Mass Torts Made Perfect Seminar

Put it on your calendars, Anapol Schwartz attorney James Ronca will be speaking on “Topamax: What You Need to Know, The Science and the Litigation” from 10:45 am to 11:15 am at the semi-annual Mass Torts Made Perfect Seminar in Las Vegas, Nevada on October 13, 2011. The acclaimed national event for Pharmaceutical and Medical Device Mass Torts will celebrate its 10th anniversary at The Bellagio Hotel and Casino in Las Vegas.

Mr. Ronca is a vital part of Anapol Schwartz Dangerous Drug and Medical Device team and is intimately involved with Topamax litigation along with partner Sol Weiss, who is co-liaison counsel to the coordinated litigation. You can register for the event online here or by calling (800) 320-2227. The cost of registration is $1,395 for lawyers and $995 for paralegals or administrators for firms; a $300 discount is obtainable for all affiliates of The National Trial Lawyers.

Mass torts can be separated from other kinds of personal injury cases by numerous key attributes. For one, they employ large amounts of claims that correspond to one product. Secondly, regardless of the large number of individuals involved, there is a similar nature to the facts and legal implications of the cases. Thirdly, there is interconnectedness between all the separate cases. Such is the case with Topamax, a drug used to treat epileptic seizures and other disorders that has also been linked to causing birth defects. If you’ve been injured by Topamax or another dangerous drug, call 1-866-735-2792 to contact the Pennsylvania dangerous drug attorneys at Anapol Schwartz today.